Navigation Links
Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
Date:1/24/2013

NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ: MAPP) concerning the proposed acquisition of the Company by Allergan, Inc. ("Allergan") in a transaction valued at approximately $958 million.    

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On January 24, 2013, MAP announced that it had entered into a definitive agreement pursuant to which the Company will be acquired by Allergan.  Under the terms of the agreement, MAP shareholders will receive $25.00 for each share owned. 

Our investigation concerns whether the MAP board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders. 

If you own MAP shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
2. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
3. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
4. VWR Funding, Inc. Announces Proposed Offering Of Senior Secured Term Loan Due 2017
5. FDAnews announces Biopharmaceutical Good Distribution Practices Summit
6. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
7. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
8. BD Announces Webcast of Annual Meeting of Shareholders
9. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
10. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
11. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the mission-driven ... to a new, more expansive office space in order to accommodate its growing ... distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway and ...
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing ... website has recently developed and published an informational resource that addresses frequently asked ... on common inquiries the site’s team of third party administrator (TPA) contributors regularly ...
Breaking Medicine News(10 mins):